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Abstract 
Background: Asthma is a multifactorial disease for which a variety of mouse models have been developed. A major 
drawback of these models is represented by the transient nature of the airway pathology peaking 24–72 h after chal-
lenge and resolving in 1–2 weeks. We characterized the temporal evolution of pulmonary inflammation and tissue 
remodeling in a recently described mouse model of chronic asthma (8 week treatment with 3 allergens: Dust mite, 
Ragweed, and Aspergillus; DRA).
Methods: We studied the DRA model taking advantage of fluorescence molecular tomography (FMT) imaging using 
near-infrared probes to non-invasively evaluate lung inflammation and airway remodeling. At 4, 6, 8 or 11 weeks, cath-
epsin- and metalloproteinase-dependent fluorescence was evaluated in vivo. A subgroup of animals, after 4 weeks of 
DRA, was treated with Budesonide (100 µg/kg intranasally) daily for 4 weeks.
Results: Cathepsin-dependent fluorescence in DRA-sensitized mice resulted significantly increased at 6 and 8 weeks, 
and was markedly inhibited by budesonide. This fluorescent signal well correlated with ex vivo analysis such as 
bronchoalveolar lavage eosinophils and pulmonary inflammatory cell infiltration. Metalloproteinase-dependent 
fluorescence was significantly increased at 8 and 11 weeks, nicely correlated with collagen deposition, as evaluated 
histologically by Masson’s Trichrome staining, and airway epithelium hypertrophy, and was only partly inhibited by 
budesonide.
Conclusions: FMT proved suitable for longitudinal studies to evaluate asthma progression, showing that cathep-
sin activity could be used to monitor inflammatory cell infiltration while metalloproteinase activity parallels airway 
remodeling, allowing the determination of steroid treatment efficacy in a chronic asthma model in mice.
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Airways remodeling
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Background
Asthma is a multifactorial and multicellular disease, and 
relevant animal models are needed for a better under-
standing of the pathophysiology of asthma and for the 
development of new therapeutic approaches. A variety of 
mouse models have been described that capture specific 
inflammatory mechanisms of asthma [1], but major 
drawbacks are represented by the transient nature of the 
airway pathological response, that peaks at 24–72 h after 
sensitization-challenge and resolve in 1–2  weeks [2, 3], 
and the development of tolerance after chronic exposure 
to single allergens [4, 5].
Recently a mouse model of chronic asthma has been 
described by Goplen [6], where the sensitization of 
Balb-C mice for 8  weeks with a combination of 3 natu-
ral allergens relevant for humans (dust mite, ragweed, 
and aspergillus: DRA) breaks through tolerance and 
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establishes chronic features of asthma. Chronic DRA 
administration leads to inflammation and epithelial 
hyperplasia reaching a maximum score at the end of 
the sensitization protocol (week 8), with pathological 
changes that persist for 2–3 weeks after the last allergen 
exposure, even if with a lower degree of severity. Unfor-
tunately, the conventional assessments of asthma in mice 
often rely on invasive measures of pulmonary function, 
ex vivo characterization of pulmonary cellular infiltration 
and observation of anatomical changes, such as airway 
remodeling due to inflammation, an approach that, while 
used extensively and highly validated, preclude the possi-
bility of repeated, longitudinal assessment of test animals. 
Recently, non invasive MRI and micro-CT techniques 
have been applied to longitudinal monitoring of airway 
remodeling in murine asthma models [7, 8], and to assess 
lung fluid accumulation as well as the anti-inflammatory 
effects of S1P(1) receptor activation in allergen-induced 
lung inflammation [9, 10], opening the possibility to non-
invasively visualize and quantitate inflammatory features 
of mouse asthma models in vivo.
Clinical visualization of asthma has largely been based 
on imaging methods such as high resolution CT, posi-
tron emission tomography (PET), single photon emis-
sion computed tomography (SPECT), and magnetic 
resonance imaging (MRI), that have been applied to the 
visualization of mechanical and physiological responses, 
for example diaphragmatic motion, pulmonary perfusion 
and ventilation as well as airway remodeling [11–14]. The 
techniques used in clinical imaging such as MRI, CT and 
PET, have been further adapted to small animal research 
and used in murine models of asthma [7–9, 15, 16], to 
serve as a preclinical, translational step between basic 
discovery and clinical practice, while imaging techniques 
developed in experimental settings may also slowly make 
their way into the clinical practice, especially in the con-
text of intraoperative activities [17, 18]. Among these 
latter, fluorescence molecular tomography (FMT) is a 
relatively new tomographic imaging technique involving 
principles similar to X-ray CT but based on the use of 
target-specific molecular fluorescent reporters and volu-
metric reconstruction of light emitted from the probes 
[19].
In the present paper we report on the possibility to 
use near-infrared imaging agents, in combination with 
FMT imaging, for the non-invasive quantitative imaging 
of mouse lung inflammation in the DRA mouse model. 
The results obtained with both a cathepsin-activable and 
a metalloproteinase-activable fluorescent agents well cor-
related with ex  vivo read-outs such as bronchoalveolar 
lavage cell analysis, pulmonary inflammatory cell infil-
trations, and histological analysis of airway epithelium 
hyperplasia and collagen deposition, allowing differential 
monitoring of cellular infiltration or tissue remodeling 
during the inflammatory response associated with DRA.
Methods
Animals
Female Balb-C (7–8 week-old) mice were purchased from 
Charles River Laboratories Italy (Calco, Lecco, Italy). 
Animals were maintained under conventional housing 
conditions. Prior to use animals were acclimated for at 
least 5 days to the local vivarium conditions (room tem-
perature: 20–24  °C; relative humidity: 40–70  %), having 
free access to standard mouse chow and tap water. All 
animal experiments described herein were approved 
by the intramural animal-welfare committee for ani-
mal experimentation of Chiesi Farmaceutici and comply 
with the European Directive 2010/63 UE, Italian D.Lgs 
26/2014 and the revised “Guide for the Care and Use of 
Laboratory Animals” [20].
DRA induction protocol
Mice, under light isoflurane anesthesia, were treated 
intranasally (i.n.) with a 30  µL volume (15  µL into each 
nostril) of DRA solution containing 5  µg of dust mite 
(extracts of Dermatophagoides farinae, Greer Labora-
tories, NC, USA), 50 µg of ragweed (extracts of Ambro-
sia artemisiifolia, Greer Lab) and 5  µg of Aspergillus 
(extracts of Aspergillus fumigatus, Greer Lab), twice a 
week for 8 weeks. The control group received 30 µL (15 
µL into each nostril) of saline i.n. using the same pro-
tocol. Among the animals undergoing DRA challenge a 
group was treated with 100 μg/Kg budesonide i.n. 6 day/
week for 4 weeks starting at the end of week 4. Eight mice 
were used for every group and the experiment was repli-
cated three times.
In vivo fluorescent imaging
DRA-challenged and control mice were injected intra-
venously with ProSense680 (Perkin Elmer, Hanover, CA, 
USA) or MMPSense680 (Perkin Elmer) at 80 nmoles/
Kg on weeks 4, 6, 8 (i.e., few minutes after the last intra-
nasal administration of DRA), and 11, and imaged 24 h 
after probe injection. ProSense680 is a fluorescent in vivo 
imaging agent that is activated by proteases such as Cath-
epsin B, L, S and Plasmin, and MMPSense680 is a fluo-
rescent in vivo imaging agent that is activated by matrix 
metalloproteinases (MMPs) including MMP-2, -3, -9 and 
-13. ProSense 680 and MMPSense 680 are optically silent 
in its unactivated state and becomes highly fluorescent 
following protease-mediated cleavage.
At the 4  weeks time point, animals were randomised 
to budesonide and control treatments according to 
the intensity of the fluorescent signal resulting from 
ProSense680.
Page 3 of 13Stellari et al. J Transl Med  (2015) 13:336 
Mice were anaesthetized using isoflurane and depilated 
to minimize fur interference with fluorescent signal. Depil-
atory cream was applied thickly on skin over the upper 
torso (front, back, and sides) of each mouse, rinsed off with 
warm water, and reapplied until all fur had been removed.
DRA-challenged and control mice were then imaged 
using the FMT 2500 in vivo imaging system (VisEn Medi-
cal, Inc., Bedford, MA, USA). Briefly, the anesthetized 
mice were carefully positioned in the imaging cassette, 
which was then placed into the FMT imaging chamber. 
A near infrared (NIR) laser diode transilluminated (i.e., 
passed light through the body of the animal to be col-
lected on the opposite side) the thorax region, with sig-
nal detection occurring via a thermoelectrically cooled 
charge-coupled device camera placed on the opposite 
side of the imaged animal. Appropriate optical filters 
allowed collection of both fluorescence and excitation 
data sets, and the multiple source-detector fluorescence 
projections were normalized to the paired collection 
of laser excitation data. The entire image acquisition 
sequence took approximately 4–5 min per mouse.
The collected fluorescence data were reconstructed by 
FMT 2500 system software version 2.2 (PerkinElmer) 
for the quantification of three-dimensional fluorescence 
signal within the lungs. Three-dimensional regions of 
interest were drawn in the upper torso encompass-
ing the lung region (below the manubrium and above 
the liver) excluding 2  mm ventrally and 3  mm dorsally. 
The total amount of lung fluorescence (in picomoles) 
and the fluorescence volume (in cubic millimeters) were 
automatically calculated from the fluorescence of inter-
nal standards generated with known concentrations of 
appropriate NIR dyes. The same mice were submitted 
to both probes, and have been evaluated at 4–6–8 and 
11 weeks: first the animals were injected with ProSense, 
and after 24–36  h MPPSense 680 was injected, after 
screening the residual fluorescence signal by FMT.
Bronchoalveolar lavage fluid collection, cell counting 
and cytokine determination
Animals were anaesthetised with isoflurane and sacri-
ficed by bleeding from the abdominal aorta. Eight mice 
were used for every time points and the experiment was 
replicated three times.
Bronchoalveolar lavage was performed and bronchoal-
veolar lavage fluids (BALFs) were collected as previously 
described [21]. Briefly, mouse tracheas were cannulated 
with a 18-gauge angiocathether. BALF was performed 
by gently washing the lungs with 0.6 mL sterile solution 
[Hank’s balanced salt solution (HBSS)  ×  10; (EDTA) 
100  mM; 4-(2-hydroxy-ethyl)-1-piperazineethansul-
phonic acid (HEPES) 1  mM; distilled water] for three 
times in the bronchial tree and collected for subsequent 
analysis. After centrifugation at 400g for 10 min, the BAL 
supernatants were frozen at −80  °C. The cell pellet was 
re-suspended in 0.2 mL of PBS. Cell number and differen-
tial count were performed with an automatic cell counter 
(Dasit XT 1800J, Cornaredo, Milano, Italy). Supernatants 
were used for simultaneous quantitation of multiple 
cytokines/chemokines using a Bio-Plex™ Cytokine Assay 
Kit (Bio-Rad Laboratories, Segrate, Milano, Italy) accord-
ing to the manufacturer instructions.
Flow cytometric analysis of BAL cells
Twenty-four hours after the last DRA challenge, BAL was 
performed and cells were subsequently analyzed for sur-
face markers. Cells were labelled in phosphate buffered 
saline (PBS, Euroclone) and 0.5  % bovine serum albu-
mine (BSA, Milteny Biotech) with fluorochrome-labeled 
monoclonal antibodies: anti mouse CD 45 PE-Cy5 (BD 
Pharmigen), anti mouse F4/80 Alexa 488 (AbD Serotec), 
anti mouse Lys6G (BD Pharmigen), anti mouse CD11b 
PE-Cy7 (BD Pharmigen) and appropriate isotype con-
trols for 30  min at RT in the dark. Cells were washed 
before and after the staining and resuspended in 300 µL 
of PBS/BSA. Samples were collected on a FACS Canto 
II (2 lasers, 6 colors, Becton–Dickinson) and analyzed 
using Diva 7 software. Mean Fluorescence Intensity 
(MFI) was determed on a statistically significant num-
ber of cells each sample. To positively select all leuko-
cytes in BAL and discard debris, gating was performed 
on CD45 positive cells. Anti-mouse F4/80 was used to 
discriminate granulocyte population, including eosino-
phils and neutrophils, from macrophages. Lymphocytes 
were gated out based on forward scatter (FSC) and side 
scatter (SSC). Moreover anti-mouse GR1+ was used to 
negatively gate out all neutrophils. FACS analysis finally 
quantitated CD11b surface activation marker expression 
on the remaining population of monocytes/macrophages 
characterized as CD45+ F4/80+ GR1− cells.
Histological processing of lung and morphometric analysis
Eight mice were used for every time points and the 
experiment was replicated three times. Lungs were col-
lected, gently inflated with 10 % neutral buffered formalin 
(about 1 mL) through a tracheal blunt needle, immersed 
in formalin and embedded longitudinally en bloc. Histo-
logical sections  (3  µm) were stained with hematoxylin/
eosin, alcian blue/PAS and Masson’s trichrome stains. In 
the haematoxylin/eosin stained sections, the following 
parameters were evaluated: airways epithelium hypertro-
phy/hyperplasia, perivascular/peribronchial/interstitial 
inflammation, pulmonary tissue infiltration of inflam-
matory cells, and vascular smooth muscle hypertrophy. 
Sections were semi-quantitatively scored as follows: 0, 
absent; 1, minimal; 2, slight; 3, moderate.
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The alcian blue/PAS histochemical stain was used 
in order to characterize the glycoprotein component 
of goblet cells in the respiratory epithelium. Sections 
were semi-quantitatively scored, based on the amount 
of alcian blue/PAS positive cells observed, as follows: 0: 
absent/rare; 1: minimal (1–30 %); 2: slight (31–60 %); 3: 
moderate (>60 %).
The Masson’s trichrome histochemical stain was used 
to evaluate the amount of collagen deposition around 
the airways. Sections were semi-quantitatively scored 
as follows: 0, absent; 1: minimal (1–30  % of structures 
involved); 2: slight (31–60  % of structures involved); 3: 
moderate (>60 % of structures involved).
To evaluate the pulmonary inflammatory infiltrate 
and the airway epithelial hyperplasia in lung specimens, 
seven airways per mouse were taken into consideration. 
In order to be considered suitable for this evaluation, 
airways needed to be completely intact and entirely con-
tained in a 200× microscopic field. Oblong airways were 
excluded from the analysis.
Pulmonary inflammatory infiltrate and airway epithe-
lial hyperplasia, quantified in digitally acquired images 
analyzed with SIS software (Soft Imaging System GmbH, 
Münster, Germany), were measured as the area of inflam-
matory infiltrates and the area of epithelium (in square 
micrometers) divided by the airway’s basement mem-
brane perimeter (in micrometers).
In detail, airway measurements included the perim-
eter of the basal membrane of the epithelium (AP), the 
area of the region circumscribed by the basal membrane 
(AA), the area of the lumen (AL) and the area covered 
by inflammatory infiltrates (AII). The airway epithelial 
hyperplasia score, corresponding to (AA − AL)/AP and 
the pulmonary inflammatory infiltrate score, correspond-
ing to AII/AP, were calculated for each airway. A mouse 
mean score and a mean total score for each group of mice 
were then calculated.
Data analysis
Data were expressed as the mean and s.e. of the mean 
of n animals. The inhibition values reported in differ-
ent Figures represents the comparison, at a given time 
point, between the increase of the observed values 
above the dashed line (representing the average value 
of control animals receiving saline instead of DRA) 
reported in the absence and that reported in the pres-
ence of budesonide. Statistical analysis was performed 
using one-way ANOVA followed by Dunnett’s t test 
for multiple comparison (PRISM Statistical software 
v 4.0.3). P  <  0.05 was considered a level of statistical 
significance.
Results
In agreement with the results of Goplen et al. [6], treat-
ment with DRA for 8  weeks, twice a week, established 
an inflammatory pulmonary phenotype characterized by 
a massive inflammatory cells infiltration in the airways, 
as shown by the marked increase in the number of total 
white cells in BALFs (Fig.  1a), with eosinophils repre-
senting the prevalent population (Fig. 1b), together with 
lymphocytes (Fig.  1c) and neutrophils (Fig.  1d). Treat-
ment with budesonide i.n. daily, starting at 4 weeks and 
continuing up to 8  weeks of DRA, markedly inhibited 
eosinophils and lymphocytes recruitment at 6 weeks (85 
and 64  % inhibition when compared to saline-treated 
animals, respectively) and 8 weeks (72 and 52 % inhibi-
tion when compared to saline-treated animals, respec-
tively) (Fig. 1b, c). The inhibition of neutrophil infiltration 
resulted much less pronounced and was statistically sig-
nificant only at the 6 weeks time-point (Fig. 1d). Inflam-
matory cell infiltrate substantially resolved at 11  weeks, 
where the total number of cells was not statistically dif-
ferent from saline-treated controls.
Infiltration of monocytes into the airways following 
DRA chronic exposure resulted in increased number 
of monocyte/macrophages in BALFs (Fig.  2a), with an 
increased expression of the integrin CD11b (Fig.  2b, c); 
treatment with budesonide significantly inhibited the 
infiltration of monocytes, reducing the number of mono-
cytes/macrophages as well as their expression of the inte-
grin adhesion molecule CD11b (Fig. 2a, b, d).
Out of 23 cytokines evaluated in BALFs, 6 resulted 
elevated upon DRA administration, and budesonide sta-
tistically inhibited the increase of IL-17 both after 6 and 
8 weeks of DRA. Interestingly, the inhibition of TNFα and 
IL-8 resulted statistically significant only after 6 weeks of 
DRA, while IL-5 and IL-10 concentrations were markedly 
affected only after 8 weeks of DRA (Fig. 3).
In vivo imaging of the cathepsin-activated near infra-
red fluorescent probe ProSense680, carried out at differ-
ent times on separate groups of animals, in parallel with 
the groups used for BALFs fluid collection and histologi-
cal analysis, showed a statistically significant increase in 
fluorescent signal as a result of DRA administration 
(Fig.  4a, b), an increase that also resulted inhibited by 
budesonide treatment by 85 and 60 % at 6 and 8 weeks, 
respectively (Fig. 4a, b). The fluorescent signal well cor-
related with the number of inflammatory cells in BALFs 
observed at 8 weeks (r2 0.997; Fig. 4c), while at 11 weeks 
it was reduced near to basal values (Fig.  4b), in parallel 
with the observed decrease of inflammatory cell infiltra-
tion into the airways (Fig. 1a). Ex vivo imaging of excised 
lungs confirmed that the fluorescence observed upon 
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ProSense and MMPSense administration was associated 
with the lungs (Additional file 1: Figure S1).
Changes in the results of the histological analysis of 
inflammatory cell infiltrate in saline, DRA and bude-
sonide treated animals (Fig. 5a), at different time points, 
well correlated with the number of inflammatory cells 
in BALFs as well as with the ProSense680 fluorescence 
signals.
The quantitative imaging of fluorescence result-
ing from the metalloproteinase-activated NIRF probe 
MMPSense680 also showed a significant increase in DRA 
animals at 8  weeks, but, unlike ProSense680, it did not 
resolve at 11 weeks (Fig. 6a, c), when inflammatory cells 
were not present anymore (Fig. 1a). Although the pmoles 
of fluorescence signal calculated in the ROI region may 
produce pictures suggesting a distribution not perfectly 
symmetrical, this is mostly due to light scattering and we 
could not discriminate if a single lobe was carrying more 
inflammation. On the other end, histological analysis of 
collagen deposition at 11 weeks showed score values still 
significantly increased in DRA animals when compared 
to saline-treated animals, in agreement with the ongoing 
Fig. 1 Cellular infiltration into the lung of DRA challenged mice. Total cells (a), eosinophils (b), lymphocytes (c) and neutrophils (d) infiltration into 
BALFs from DRA challenged mice treated with either saline or budesonide at different time points. Values are expressed as number of cells per μL 
as measured by Dasit Sysmec XT 1800. The dashed line represents the average value of control animals treated with saline. Eight mice were used for 
every time points and the experiment was replicated three times. Values are expressed as mean ± SEM of the three different experiments. Statistical 
differences were tested by one-way ANOVA followed by Dunnett’s t post hoc test for group comparisons. *P < 0.05 and **P < 0.01 vs time-matched 
DRA group
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process of airways remodeling that is known to outlast 
inflammatory cell infiltration within the airways (Fig. 6c). 
A similar evolution was observed for the histological 
scoring of airways epithelium hypertrophy/hyperplasia, 
where values significantly higher than those observed in 
saline treated animals were still observable at 11  weeks 
(Fig. 5b), and similar results were observed upon quanti-
tation of goblet cell scores (Fig. 5c). Representative histol-
ogies of Masson’s trichrome stain and Alcian/PAS of lung 
sections obtained after 11 weeks of DRA are presented in 
Additional file 2: Figure S2.
Budesonide treatment inhibited by about 50  % 
MMPSense680 fluorescent signal at 8 and 11  weeks 
(Fig.  6a, c), an effect that goes hand in hand with the 
observed inhibition of collagen deposition (Fig.  6b) 
and of the airways epithelium hypertrophy/hyperplasia 
(Fig. 5b).
Discussion
In the present study we provide evidence about the possi-
bility to monitor in vivo in mice inflammatory cells infil-
tration and tissue remodeling associated with repeated 
Fig. 2 a Number of monocytes/macrophages in BALF from control and DRA challenged mice treated with either saline or budesonide at different 
time points. Values are expressed as number of cells per μL as measured by Dasit Sysmec XT 1800. The dashed line represents the average value of 
control animals treated with saline. b Expression of CD11b integrin surface marker on monocytes/macrophages present in BALFs as measured by 
FACS analysis in BALF from DRA challenged mice treated with either saline or budesonide at different time points. Values are expressed as Mean 
Fluorescence Intensity (MFI). The dashed line represents the average value of control animals treated with saline. c Representative picture of CD11b 
integrin surface marker on monocytes measured by FACS analysis; CD11b expression of mice treated with either saline (dark grey) or 8 weeks of DRA 
(black), with isotype control being depicted in light grey. d Representative picture of CD11b integrin surface marker on monocytes measured by 
FACS analysis; CD11b expression of mice treated with either saline (dark grey) or 8 weeks of DRA and budesonide beginning after 4 weeks of DRA 
(black), with isotype control being depicted in light grey. Eight mice were used for every time points and the experiment was replicated three times. 
Values are expressed as mean ± SEM of the three different experiments. Statistical differences were tested by one-way ANOVA followed by Dun-
nett’s t post hoc test for group comparisons. *P < 0.05 and **P < 0.01 vs time-matched DRA group
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exposures to a combination of three natural allergens rel-
evant for humans.
In agreement with previously published results [6] 
the present study confirms that multiple allergen expo-
sure of mice breaks tolerance and induces a persisting 
airway pathology that is more closely mimicking the 
features of asthma in humans. Eight weeks of repeated 
allergen exposure cause a long lasting infiltration of 
inflammatory cells into the airways as well as pulmonary 
inflammation and histopathological lesions. Increased 
number of inflammatory cells such as eosinophils, neu-
trophils, monocytes/macrophages and lymphocytes 
were observed in BALFs and in pulmonary tissue up to 
8  weeks after starting DRA administration, while colla-
gen deposition, together with epithelial hyperplasia, were 
evident upon morphometric analysis at the later time 
points. Three weeks after stopping the exposure to aller-
gen, cellular infiltration into the airways and the pulmo-
nary tissue was almost completely resolved, but markers 
of the remodeling process such as collagen deposition, 
and airways epithelium hypertrophy/hyperplasia per-
sisted, outlasting, as expected, the airways inflammatory 
cell infiltration [22].
Eosinophil infiltration is a hallmark of the pulmo-
nary allergic inflammatory response, and markedly 
increased numbers of eosinophils were recovered in 
BALFs upon DRA administration. Eosinophil infiltra-
tion was very sensitive to the treatment with budesonide 
that strongly inhibited the increase in eosinophils both 
2 and 4 weeks after the beginning of the treatment (that 
is after 6 and 8  weeks of DRA exposure). Interestingly, 
budesonide markedly decreased the concentrations of 
Fig. 3 Cytokines determination in BALFs. Control and DRA challenged mice treated with either saline or budesonide were sacrificed at 6 or 8 weeks 
and a panel of 23 cytokines was analysed using a Bio-Plex™ Cytokine Assay Kit (Bio-Rad Laboratories). Eight mice were used for every time points 
and the experiment was replicated three times. Values are expressed as mean ± SEM fold-increase vs the average of the control group of the three 
different experiments. Statistical differences were tested by one-way ANOVA followed by Dunnett’s t post hoc test for group comparisons. P < 0.05 
vs time-matched DRA group
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the potent maturation, differentiation and activation fac-
tor for eosinophils IL-5 [23] only at the latest time point 
(8  weeks of DRA) but did not affect the increased con-
centrations of IL-5 observed 2 weeks into the treatment 
with the topical corticosteroid (that is 6  week of DRA). 
This result supports the notion that the effects of corti-
costeroid treatment are not simply mediated through the 
prevention of IL-5 release from cells within the lung, and 
is in agreement with a previous observation, obtained in 
a different mouse model of allergic asthma, showing the 
Fig. 4 a In vivo imaging of representative control, DRA-challenged and DRA-challenged and budesonide-treated mice injected with Prosense680 
after 8 weeks of DRA. b Fluorescence signal quantification measured by FMT in ProSense680-injected mice at different time points after begin-
ning of DRA, in the absence or presence of budesonide treatment beginning after 4 weeks of DRA. Values are expressed as mean ± SEM of three 
different experiments. The dashed line represents the average value of control animals treated with saline. c Linear regression between the intensity 
of fluorescence resulting from ProSense680 and the total number of cell in BAL fluids from control, DRA-challenged and DRA-challenged and bude-
sonide-treated mice injected with Prosense680 after 8 weeks of DRA. Eight mice were used for every time points and the experiment was replicated 
three times. Values are expressed as mean ± SEM of the three different experiments. Statistical differences were tested by one-way ANOVA followed 
by Dunnett’s t post hoc test for group comparisons. P < 0.05 and **P < 0.01
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effect of corticosteroids on eosinophils preceding that on 
the concentrations of IL-5 [24].
Repeated exposure to low-dose allergen have been 
reported to increase the expression of CD11b on alveo-
lar monocytes/macrophages, consistent with an influx 
of monocytes [25]; DRA exposure also resulted in an 
increased number of monocyte/macrophages in BALFs, 
together with an increased expression of the adhesion 
molecule CD11b, as a result of a raising proportion of 
monocytes in the alveolar macrophage population [26, 27].
Treatment with budesonide also reduced the num-
ber of neutrophils infiltrating into the airways, but this 
effect was only observed at the earliest observation 
point (2  weeks of budesonide treatment, 6  weeks of 
DRA), while no inhibition was evident after 4  weeks of 
treatment (8  weeks of DRA). This effect well correlated 
with the changes in BALFs concentrations of the potent 
neutrophil chemotactic factor IL-8 [28], and is in agree-
ment with previously published results [29].
Recent breakthroughs in photonic technology have 
allowed the advance of optical imaging beyond stand-
ard, low penetration two-dimensional fluorescence 
reflectance imaging (FRI) to allow for three dimensional 
fluorescent tomographic in  vivo imaging systems. Such 
technology has opened the door not only to deep-tissue 
detection and localization but also to the new capabil-
ity of absolute quantification of fluorescence at any site 
within the body.
This and other optical imaging techniques could also 
be used in animal studies to validate probes, such as 
Fig. 5 a Pulmonary inflammatory cell infiltrate at different time-points after the beginning of DRA in the absence or presence of budesonide 
treatment beginning after 4 weeks of DRA. Eight mice were used for every time points and the experiment was replicated three times. Score values, 
determined as described in "Methods", are expressed as mean ± SEM of the three different experiments. The dashed line represents the average 
value of control animals treated with saline. b Airway epithelium hypertrophy at different time-points after the beginning of DRA in the absence or 
presence of budesonide treatment beginning after 4 weeks of DRA. Eight mice were used for every time points and the experiment was replicated 
three times. Score values, determined as described in "Methods", are expressed as mean ± SEM of the three different experiments. c Goblet cells 
quantitation at different time-points after the beginning of DRA in the absence or presence of budesonide treatment beginning after 4 weeks of 
DRA. Eight mice were used for every time points and the experiment was replicated three times. Score values, determined as described in “Meth-
ods”, are expressed as mean ± SEM of the three different experiments. The dashed line represents the average value of control animals treated with 
saline. Statistical analysis was carried out by one-way ANOVA followed by Fischer’s exact test. P < 0.05 and **P < 0.01
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peptides/antibodies that may then be used in humans 
by replacing the fluorescent marker with a radioisotope 
allowing nuclear medicine imaging [30].
Eosinophils are known to produce a variety of proteases 
and lysosomal cysteine proteases, including cathepsins B, 
L, and S [31, 32]. Such proteases may be relevant in the 
pathogenesis of asthma and other pulmonary diseases, 
through their contribution to extracellular matrix deg-
radation [33] and the modulation of immune responses 
[34]. Metalloproteinase (MMP) may also play a role in 
pulmonary diseases such as asthma, COPD and inter-
stitial lung diseases, where an unbalance between their 
activity and the activity of endogenous inhibitors (tissue 
inhibitors of metalloproteinases: TIMPs) is considered a 
key event [35–37], and MMP inhibition is an attractive 
therapeutic target [38]. Structural cells such as fibro-
blasts, bronchial and alveolar epithelial cells, and smooth 
muscle cells [39–41] as well as inflammatory cells such as 
neutrophils, alveolar macrophages, mast cells and eosin-
ophils [42–44] are known to synthesize MMP in the lung. 
Fig. 6 a In vivo imaging of representative control, DRA-challenged and DRA-challenged and budesonide-treated mice injected with MMPSense680 
after 11 weeks from the beginning of DRA administration (3 weeks after ending of DRA administration). b Score of collagen deposition measured by 
Masson’s Trichrome staining at different time points after beginning of DRA, in the absence or presence of budesonide treatment beginning after 
4 weeks of DRA. Values are expressed as mean ± SEM of three different experiments. The dashed line represents the average value of control animals 
treated with saline. c Fluorescence signal quantification measured by FMT in MMPSense680-injected mice at different time points after beginning 
of DRA, in the absence or presence of budesonide treatment beginning after 4 weeks of DRA. Eight mice were used for every time points and the 
experiment was replicated three times. Values are expressed as mean ± SEM of the three different experiments. The dashed line represents the 
average value of control animals treated with saline. Statistical differences were tested by one-way ANOVA followed by Dunnett’s t post hoc test for 
group comparisons. P < 0.05 and **P < 0.01
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Taking advantage of cathepsin-sensitive (ProSense680) 
and metalloproteinase-sensitive (MMPSense680) near-
infrared fluorescent agents associated with FMT, we 
monitored the activity of these proteinases within the 
lungs of mice at different times during the DRA adminis-
tration, finding that fluorescent signal intensity well cor-
related with specific inflammatory responses, as assessed 
in parallel groups of animals. In particular, cathepsin 
activity provided results that quantitatively correlated 
with the number of inflammatory cells in BALFs, while 
MMP activity better correlated with remodeling pro-
cesses such as collagen deposition. Although it cannot 
be ruled out that the correlations observed may only be 
circumstantial, the results obtained with post-mortem 
bronchoalveolar lavage (BAL) fluid analyses, cells counts, 
and histology at different time points all support the cor-
relation between inflammatory cell infiltration/remod-
eling and the in vivo fluorescence signals observed,
Treatment with budesonide of mice undergoing DRA 
with already established pulmonary inflammation, 
decreased both the conventionally assessed inflammation 
parameters and cathepsin- and MMP-derived fluores-
cence, providing evidence that FMT allows the quanti-
tative evaluation of the activity of corticosteroids in this 
recently described experimental model of asthma, both 
on inflammatory cells pulmonary infiltration and, at least 
partially, on tissue remodeling.
FMT using NIRF probes such as ProSense680 and 
MMSense 680 has been successfully used to assess pul-
monary inflammation in LPS-treated [45, 46] and in 
ovalbumin-sensitized and challenged mice [46], as well 
as to evaluate the effect of corticosteroid in ovalbumin-
sensitized and challenged mice [46, 47]. More recently, 
alternative NIRF probes targeting selectin adhesion mol-
ecules have also been used to monitor the recruitment 
of inflammatory cells in ovalbumin-sensitized and chal-
lenged mice [48, 49] and, again, the efficacy of steroids in 
suppressing allergic inflammatory response in the lung 
[49].
Nevertheless in all these studies FMT was used to 
monitor acute inflammatory responses, either caused by 
sensitization and challenge or by exposure to LPS, and/or 
the effect of corticosteroid treatment on such a response. 
In our study, the use of a recently described chronic 
asthma model in mice together with in vivo FMT imag-
ing, allowed real time evaluation of activities associated 
with chronic allergic inflammation in the lung, enabling 
longitudinal non-invasive consecutive examinations.
The long lasting allergic inflammatory response 
observed in this model also allowed the evaluation of the 
therapeutic intervention with topical budesonide, rather 
than the prophylactic activity of corticosteroid assessed 
in other studies [46, 47, 49]. Indeed, randomization 
to treated and control groups using the FMT results of 
ProSense680 carried out after 4  weeks of DRA admin-
istration, minimizes variability by equally representing, 
in the control and budesonide-treated group, animals 
with different responses to DRA, therefore maximizing 
the possibility to assess statistically significant differ-
ences associated to treatment using a limited number of 
animals.
In vivo FMT imaging allowed to monitor non invasively 
and throughout the 11  weeks of the protocol, different 
component of the pulmonary inflammation associated 
with this novel model of chronic asthma, overcoming 
one of the mayor limitations for the use of asthma mouse 
models where conventional assessments of inflammation 
and asthma progression rely on invasive measures of pul-
monary function and ex vivo characterization of pulmo-
nary cellular infiltration. Although these assessments of 
disease status are used extensively and highly validated, 
they are terminal procedures that preclude the possibility 
of repeated, longitudinal assessment of test subjects.
Conclusions
We studied a recently described, chronic asthma model 
resulting from an eight-week, twice a week, intranasal 
challenge with triple allergens (DRA) in female Balb/C 
mice. In addition to confirming that this model better 
reproduces the feature of human chronic asthma with 
inflammatory cell infiltrates associated with epithelial 
hyperplasia that last throughout the period of allergen 
administration and beyond, we also demonstrated the 
ability of the FMT imaging to non invasively monitor 
and quantify different components of the inflammatory 
response in the lung in a robust and consistent manner. 
The use of a cathepsin-sensitive agent produced results 
that well correlated with cellular infiltrates within the 
airways and the pulmonary tissue. On the other side 
the results obtained with a metalloproteinase-sensitive 
agent resulted in mirroring more closely collagen depo-
sition and epithelial cell hypertrophy, therefore showing 
the potential to non-invasively monitor different com-
ponent of the inflammatory response associated with 
DRA. The consistency of the quantitative tomography 
and its excellent correlation with BAL assessment and 
histological determinations provides a powerful tool for 
monitoring the disease and quantify the efficacy of thera-
peutic agents. FMT imaging applied to asthma research, 
using new and existing near infrared fluorescent imaging 
agents, may therefore provide a novel, non-invasive tool 
for understanding pulmonary inflammation and help 
develop new therapeutics. DRA model together with 
FMT will open up a new way to look at asthma progres-
sion and the pharmacological response to treatment of 
different classes of anti-inflammatory drugs.
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